Chemours names Mary Cranston as Chair

Alister Cowan named Lead Independent Director

The Chemours Company announced that its Board of Directors has appointed Independent Director Mary Cranston as Chair of the Board and Alister Cowan to the role of Lead Independent Director, effective September 2, 2025.

These appointments follow the departure of Dawn Farrell, who has accepted a position with the Canadian government as the Chief Executive Officer of the newly created Major Projects Office under the Building Canada Act.

“While Dawn’s departure is a loss for Chemours, it is also a moment of pride. Dawn’s appointment is a testament to her exceptional leadership and deep commitment to public service,” said Denise Dignam, President and CEO of Chemours. “I welcome the leadership of Mary and Alister in their new roles—continuing the partnership we have established. I am confident that together, we will ensure the successful execution of our Pathway to Thrive strategy.”

Cranston, a director since 2015, led Chemours’ multi-year Board refresh, bringing in high-impact leaders aligned with the company’s strategic priorities. She brings decades of governance leadership experience from serving on boards of global public companies, including Visa, McAfee, and TPG, and was the Chair and CEO of Pillsbury Winthrop Shaw Pittman LLC.

Cowan, appointed to the Board in 2023, is a seasoned financial executive with over 30 years of experience, including 15 years as a public company CFO. He brings deep expertise in capital markets, risk management, and corporate development, having served as CFO of Suncor Energy and Husky Energy. Cowan chairs the Audit, Risk, and Finance Committee, positioning him to complement Chair Cranston’s board leadership with his strong financial background.